BT Group Given “Underperform” Rating at BNP Paribas (BT.A)

Share on StockTwits

BT Group (LON:BT.A)‘s stock had its “underperform” rating restated by equities researchers at BNP Paribas in a research report issued on Thursday, AnalystRatingsNetwork reports. They currently have a GBX 340 ($5.59) target price on the stock.

A number of other analysts have also recently weighed in on BT.A. Analysts at Barclays reiterated an “overweight” rating on shares of BT Group in a research note to investors on Monday. They now have a GBX 410 ($6.74) price target on the stock. Separately, analysts at Beaufort Securities upgraded shares of BT Group to a “buy” rating in a research note to investors on Monday. Finally, analysts at Nomura reiterated a “buy” rating on shares of BT Group in a research note to investors on Monday. They now have a GBX 500 ($8.22) price target on the stock. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of GBX 384.74 ($6.32).

BT Group plc is a communications services companies, serving the needs of customers in the United Kingdom and in more than 170 countries globally.

Receive News & Ratings for BT Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BT Group and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Triangle Petroleum Sees Large Growth in Short Interest
Triangle Petroleum Sees Large Growth in Short Interest
TGC Industries Sets New 12-Month Low at $2.94
TGC Industries Sets New 12-Month Low at $2.94
CIBER Reaches New 52-Week Low at $3.05
CIBER Reaches New 52-Week Low at $3.05
Northern Oil & Gas Sees Large Increase in Short Interest
Northern Oil & Gas Sees Large Increase in Short Interest
Protalix BioTherapeutics Sees Significant Increase in Short Interest
Protalix BioTherapeutics Sees Significant Increase in Short Interest
Southside Bancshares  Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Southside Bancshares Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.